Q-omics provides the consensus-scored BCL2L11 profile across patient tissues and cancer cell-line models. BCL2L11 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BCL2L11 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, BCL2L11 RNA expression shows 18,916 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, THCA, and UVM as cancer lineages where BCL2L11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL2L11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL2L11 survival associations across molecular data types. BCL2L11 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL2L11 RNA expression–survival associations across cancer types. High BCL2L11 expression shows unfavorable associations in KIRP, LAML, KICH and ACC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BCL2L11 RNA expression.
This table summarizes BCL2L11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BCL2L11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL2L11 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, BLCA, LUSC and STAD. The THCA box plot shows higher BCL2L11 RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p < 0.001).
This table shows molecular features associated with BCL2L11 in patient tissues and cancer cell lines. In patient samples, BCL2L11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL2L11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
